Compendium of Cancer Genome Aberrations

HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

[unchecked revision][unchecked revision]
← Older editNewer edit →
VisualWikitext
No edit summary
No edit summary
Line 27: Line 27:
|
|
|-
|-
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 34: Line 34:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Clonal cytopenias of undetermined significance|Clonal cytopenias of undetermined significance]]||Disease|| || || || || ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 41: Line 41:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Chronic myeloid leukaemia||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease|| || || || || ||FQR|| ||
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
Line 48: Line 48:
|
|
|-
|-
|Chronic neutrophilic leukaemia||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease|| || || || || ||FQR|| ||
|Chronic Neutrophilic Leukemia (CNL)
|Chronic Neutrophilic Leukemia (CNL)
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
Line 55: Line 55:
|
|
|-
|-
|Chronic eosinophilic leukaemia||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease|| || || || || ||FQR|| ||
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|Chelsea D. Kramish; Daynna J.Wolff
|Chelsea D. Kramish; Daynna J.Wolff
Line 62: Line 62:
|
|
|-
|-
|Polycythaemia vera||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease|| || || || || ||FQR|| ||
|Polycythemia Vera (PV)
|Polycythemia Vera (PV)
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
Line 69: Line 69:
|
|
|-
|-
|Essential thrombocythaemia||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease|| || || || || ||FQR|| ||
|Essential Thrombocythemia (ET)
|Essential Thrombocythemia (ET)
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
Line 76: Line 76:
|
|
|-
|-
|Primary myelofibrosis||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease|| || || || || ||FQR|| ||
|Primary Myelofibrosis (PMF)
|Primary Myelofibrosis (PMF)
|T. Niroshi Senaratne, UCLA
|T. Niroshi Senaratne, UCLA
Line 83: Line 83:
|
|
|-
|-
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' | || || || || ||FQR|| ||
|[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' | || || || || ||FQR|| ||
|Juvenile Myelomonocytic Leukemia (JMML)
|Juvenile Myelomonocytic Leukemia (JMML)
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
Line 94: Line 94:
|FQR has emailed SR several times, last 4/20/22
|FQR has emailed SR several times, last 4/20/22
|-
|-
|Myeloproliferative neoplasm, NOS||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease|| || || || || ||FQR|| ||
|Myeloproliferative Neoplasm (MPN), Unclassifiable
|Myeloproliferative Neoplasm (MPN), Unclassifiable
|Thomas Lee, MD, PhD, University of California, Los Angeles
|Thomas Lee, MD, PhD, University of California, Los Angeles
Line 101: Line 101:
|
|
|-
|-
|Cutaneous mastocytosis||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease|| || || || || ||FQR|| ||
|Cutaneous Mastocytosis
|Cutaneous Mastocytosis
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
Line 108: Line 108:
|
|
|-
|-
|Systemic mastocytosis||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease|| || || || || ||FQR|| ||
|Systemic Mastocytosis
|Systemic Mastocytosis
|'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University
|'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University
Line 115: Line 115:
|
|
|-
|-
|Mast cell sarcoma||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease|| || || || || ||FQR|| ||
|Mast Cell Sarcoma
|Mast Cell Sarcoma
|Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL
|Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL
Line 122: Line 122:
|
|
|-
|-
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease|| || || || || ||FQR|| ||
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
Line 129: Line 129:
|
|
|-
|-
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease|| || || || || ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 143: Line 143:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts|Myelodysplastic neoplasm with low blasts]]||Disease|| || || || || ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 150: Line 150:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm, hypoplastic|Myelodysplastic neoplasm, hypoplastic]]||Disease|| || || || || ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 157: Line 157:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myelodysplastic neoplasm with increased blasts||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease|| || || || || ||FQR|| ||
|Myelodysplastic Syndrome (MDS) with Excess Blasts
|Myelodysplastic Syndrome (MDS) with Excess Blasts
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 164: Line 164:
|
|
|-
|-
|Childhood myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease|| || || || || ||FQR|| ||
|Refractory Cytopenia of Childhood
|Refractory Cytopenia of Childhood
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 171: Line 171:
|
|
|-
|-
|Childhood myelodysplastic neoplasm with increased blasts||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease|| || || || || ||FQR|| ||
|Refractory Cytopenia of Childhood
|Refractory Cytopenia of Childhood
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 178: Line 178:
|
|
|-
|-
|Chronic myelomonocytic leukaemia||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease|| || || || || ||FQR|| ||
|Chronic Myelomonocytic Leukemia (CMML)
|Chronic Myelomonocytic Leukemia (CMML)
|Linsheng Zhang, MD, PhD
|Linsheng Zhang, MD, PhD
Line 185: Line 185:
|
|
|-
|-
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease|| || || || || ||FQR|| ||
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
|Linsheng Zhang, MD, PhD
|Linsheng Zhang, MD, PhD
Line 192: Line 192:
|
|
|-
|-
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease|| || || || || ||FQR|| ||
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
Line 199: Line 199:
|
|
|-
|-
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease|| || || || || ||FQR|| ||
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
Line 206: Line 206:
|
|
|-
|-
|Acute promyelocytic leukaemia with PML::RARA fusion
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]
|Disease
|Disease
|
|
Line 222: Line 222:
|
|
|-
|-
|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]
|Disease
|Disease
|
|
Line 238: Line 238:
|
|
|-
|-
|Acute myeloid leukaemia with CBFB::MYH11 fusion
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]
|Disease
|Disease
|
|
Line 254: Line 254:
|
|
|-
|-
|Acute myeloid leukaemia with DEK::NUP214 fusion
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]
|Disease
|Disease
|
|
Line 270: Line 270:
|
|
|-
|-
|Acute myeloid leukaemia with RBM15::MRTFA fusion
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]]
|Disease
|Disease
|
|
Line 286: Line 286:
|
|
|-
|-
|Acute myeloid leukaemia with BCR::ABL1 fusion
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
|Disease
|Disease
|
|
Line 302: Line 302:
|
|
|-
|-
|Acute myeloid leukaemia with KMT2A rearrangement
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]
|Disease
|Disease
|
|
Line 318: Line 318:
|
|
|-
|-
|Acute myeloid leukaemia with MECOM rearrangement
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]
|Disease
|Disease
|
|
Line 350: Line 350:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Acute myeloid leukaemia with NPM1 mutation
|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]]
|Disease
|Disease
|
|
Line 366: Line 366:
|Add WHO reference
|Add WHO reference
|-
|-
|Acute myeloid leukaemia with CEBPA mutation
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
|Disease
|Disease
|
|
Line 382: Line 382:
|
|
|-
|-
|Acute myeloid leukaemia, myelodysplasia-related
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]]
|Disease
|Disease
|
|
Line 398: Line 398:
|
|
|-
|-
|Acute myeloid leukaemia with other defined genetic alterations
|[[HAEM5:Acute myeloid leukaemia with other defined genetic alterations|Acute myeloid leukaemia with other defined genetic alterations]]
|Disease
|Disease
|
|
Line 414: Line 414:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Acute myeloid leukaemia with minimal differentiation
|[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]]
|Disease
|Disease
|
|
Line 430: Line 430:
|
|
|-
|-
|Acute myeloid leukaemia without maturation
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]
|Disease
|Disease
|
|
Line 446: Line 446:
|
|
|-
|-
|Acute myeloid leukaemia with maturation
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]
|Disease
|Disease
|
|
Line 462: Line 462:
|
|
|-
|-
|Acute basophilic leukaemia
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]]
|Disease
|Disease
|
|
Line 478: Line 478:
|
|
|-
|-
|Acute myelomonocytic leukaemia
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]]
|Disease
|Disease
|
|
Line 494: Line 494:
|
|
|-
|-
|Acute monocytic leukaemia
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]]
|Disease
|Disease
|
|
Line 510: Line 510:
|
|
|-
|-
|Acute erythroid leukaemia
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]]
|Disease
|Disease
|
|
Line 526: Line 526:
|
|
|-
|-
|Acute megakaryoblastic leukaemia
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]]
|Disease
|Disease
|
|
Line 542: Line 542:
|
|
|-
|-
|Myeloid sarcoma
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]]
|Disease
|Disease
|
|
Line 574: Line 574:
|
|
|-
|-
|Myeloid neoplasm post cytotoxic therapy
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]
|Disease
|Disease
|
|
Line 590: Line 590:
|Check reference format
|Check reference format
|-
|-
|Myeloid neoplasms associated with germline predisposition
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]
|Disease
|Disease
|ISSUE - FIX
|ISSUE - FIX
Line 606: Line 606:
|
|
|-
|-
|Myeloid proliferations associated with Down syndrome
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]]
|Disease
|Disease
|
|
Line 622: Line 622:
|
|
|-
|-
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]]
|Disease
|Disease
|
|
Line 638: Line 638:
|
|
|-
|-
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]]
|Disease
|Disease
|
|
Line 654: Line 654:
|
|
|-
|-
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]]
|Disease
|Disease
|
|
Line 670: Line 670:
|
|
|-
|-
|Myeloid/lymphoid neoplasm with JAK2 rearrangement
|[[HAEM5:Myeloid/lymphoid neoplasm with JAK2 rearrangement|Myeloid/lymphoid neoplasm with JAK2 rearrangement]]
|Disease
|Disease
|ISSUE- FIX
|ISSUE- FIX
Line 689: Line 689:
|
|
|-
|-
|Myeloid/lymphoid neoplasm with FLT3 rearrangement
|[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement|Myeloid/lymphoid neoplasm with FLT3 rearrangement]]
|Disease
|Disease
|ISSUE - FIX
|ISSUE - FIX
Line 705: Line 705:
|
|
|-
|-
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion
|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]]
|Disease
|Disease
|
|
Line 721: Line 721:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes
|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]]
|Disease
|Disease
|
|
Line 737: Line 737:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
|Disease
|Disease
|
|
Line 753: Line 753:
|
|
|-
|-
|Mixed-phenotype acute leukaemia with KMT2A rearrangement
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
|Disease
|Disease
|
|
Line 769: Line 769:
|
|
|-
|-
|Acute leukaemia of ambiguous lineage with other defined genetic alterations
|[[HAEM5:Acute leukaemia of ambiguous lineage with other defined genetic alterations|Acute leukaemia of ambiguous lineage with other defined genetic alterations]]
|Disease
|Disease
|
|
Line 785: Line 785:
|
|
|-
|-
|Mixed-phenotype acute leukaemia, B/myeloid
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]
|Disease
|Disease
|
|
Line 801: Line 801:
|
|
|-
|-
|Mixed-phenotype acute leukaemia, T/myeloid
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]]
|Disease
|Disease
|
|
Line 817: Line 817:
|
|
|-
|-
|Mixed-phenotype acute leukaemia, rare types
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]]
|Disease
|Disease
|
|
Line 833: Line 833:
|
|
|-
|-
|Acute leukaemia of ambiguous lineage, NOS
|[[HAEM5:Acute leukaemia of ambiguous lineage, NOS|Acute leukaemia of ambiguous lineage, NOS]]
|Disease
|Disease
|
|
Line 849: Line 849:
|
|
|-
|-
|Acute undifferentiated leukaemia
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]
|Disease
|Disease
|
|
Retrieved from "https://test.ccga.io/index.php/HAEM5:Volunteer_Assignments_and_Opportunities"